

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A method for inhibiting the development of epilepsy, comprising administering an effective amount of [[an]] a selective alpha2-adrenoceptor antagonist to a human patient at risk of developing epilepsy, wherein said risk of developing epilepsy is caused by head trauma, brain ischemia, infection, or neurosurgical operation.
2. (Previously Presented) The method according to claim 1, wherein the alpha2-adrenoceptor antagonist is atipamezole or a pharmaceutically acceptable salt thereof.
3. (Withdrawn) The method according to claim 1, wherein the alpha2-adrenoceptor antagonist is idazoxan or a pharmaceutically acceptable salt thereof.
4. (Withdrawn) The method according to claim 1, wherein the alpha2-adrenoceptor antagonist is efaxorane or a pharmaceutically acceptable salt thereof.
5. (Withdrawn) The method according to claim 1, wherein the alpha2-adrenoceptor antagonist is 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole or a pharmaceutically acceptable salt thereof.
6. (Withdrawn) The method according to claim 1, wherein the alpha2-adrenoceptor antagonist is an analog chosen from analogs of atipamezole, analogs of idazoxan, and analogs of efaxorane.
7. (Canceled).

8. (New) The method of claim 2, wherein the pharmaceutically acceptable salt is an acid addition salt with an inorganic or organic acid.